HK1042234A1 - 向肺部施加乾粉配方以治疗不育症 - Google Patents

向肺部施加乾粉配方以治疗不育症 Download PDF

Info

Publication number
HK1042234A1
HK1042234A1 HK02103235.7A HK02103235A HK1042234A1 HK 1042234 A1 HK1042234 A1 HK 1042234A1 HK 02103235 A HK02103235 A HK 02103235A HK 1042234 A1 HK1042234 A1 HK 1042234A1
Authority
HK
Hong Kong
Prior art keywords
dry powder
treating infertility
pulmonary administration
powder formulations
methods
Prior art date
Application number
HK02103235.7A
Other languages
English (en)
Chinese (zh)
Inventor
Nagarajan Sudha
S. Patton John
B. Bennett David
Greene Joanne
Chiang Hi-Shi
L. M. Stults Cheryl
Venthoye Geraldine
Lavern Allen Darrel
Lee Hughes Benjamin
Stiff-Torvik Mary
Keith Wolff Ronald
David Roeder William
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Priority claimed from PCT/US2000/009869 external-priority patent/WO2000061178A1/en
Publication of HK1042234A1 publication Critical patent/HK1042234A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK02103235.7A 1999-04-13 2000-04-13 向肺部施加乾粉配方以治疗不育症 HK1042234A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12912199P 1999-04-13 1999-04-13
US129121P 1999-04-13
US13009999P 1999-04-20 1999-04-20
US130099P 1999-04-20
PCT/US2000/009869 WO2000061178A1 (en) 1999-04-13 2000-04-13 Pulmonary administration of dry powder formulations for treating infertility

Publications (1)

Publication Number Publication Date
HK1042234A1 true HK1042234A1 (zh) 2002-08-09

Family

ID=26827234

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103235.7A HK1042234A1 (zh) 1999-04-13 2000-04-13 向肺部施加乾粉配方以治疗不育症

Country Status (7)

Country Link
US (1) US7112341B1 (enExample)
EP (1) EP1169053A1 (enExample)
JP (1) JP2002541213A (enExample)
AU (1) AU779869B2 (enExample)
CA (1) CA2369262A1 (enExample)
HK (1) HK1042234A1 (enExample)
TW (1) TWI277425B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2343124T3 (es) * 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
EP1631496B1 (en) * 2003-04-28 2014-02-26 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
JP4933439B2 (ja) * 2004-11-09 2012-05-16 アレス トレーディング ソシエテ アノニム Ｆｓｈの精製方法
EP1960419B1 (en) * 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
US7966746B2 (en) * 2006-04-24 2011-06-28 Medical Instill Technologies, LLC Needle penetrable and laser resealable lyophilization method
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
EP2563813B1 (en) 2010-04-30 2015-08-26 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
CA2842276C (en) * 2011-08-02 2020-11-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
RU2018132561A (ru) 2012-07-30 2018-11-02 Трофоген Инк. Суперагонисты гликопротеинового гормона длительного действия
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
MX2016005973A (es) 2013-11-05 2016-11-14 Trophogen Inc Superagonistas de acción prolongada de la hormona de glicoproteína.
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2017205101A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
FI3658184T3 (fi) 2017-07-27 2023-11-30 Alexion Pharma Inc Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019231983A1 (en) 2018-05-31 2019-12-05 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
AU2019370295A1 (en) 2018-10-30 2021-06-03 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
JP2023504208A (ja) 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
MX2023004621A (es) * 2020-10-23 2023-06-06 Alexion Pharma Inc Método de control del contenido total de ácido siálico (ctas) durante la fabricación de fosfatasa alcalina.
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
HU185535B (en) 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
US5156957A (en) 1983-11-02 1992-10-20 Genzyme Corporation Follicle stimulating hormone
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
DE3486469T2 (de) 1983-11-02 1999-04-15 Applied Research Systems Ars Holding N.V., Curacao Herstellung heterodimirer menschlicher Fruchtbarkeitshormone
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
EP0229810B1 (en) 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
JPS6447952A (en) * 1987-05-06 1989-02-22 Saibaafuruua Inc Immunoassay, reagent used therefor and making thereof
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE69029799T2 (de) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5270057A (en) 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
IT1250075B (it) 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
FR2754450B1 (fr) 1996-10-11 1998-12-31 3X Engineering Materiau support de microcapsules
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5990288A (en) * 1997-10-21 1999-11-23 Vitro Diagnostics, Inc. Method for purifying FSH
US6573238B2 (en) 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
JP4719357B2 (ja) 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法

Also Published As

Publication number Publication date
TWI277425B (en) 2007-04-01
JP2002541213A (ja) 2002-12-03
US7112341B1 (en) 2006-09-26
AU4082000A (en) 2000-11-14
CA2369262A1 (en) 2000-10-19
AU779869B2 (en) 2005-02-17
EP1169053A1 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
HK1042234A1 (zh) 向肺部施加乾粉配方以治疗不育症
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
WO2002070438A3 (en) Compositions for delivering bisphosphonates
NO20021800D0 (no) Törre pulverblandinger med forbedret dispergerbarhet
WO2002080884A3 (en) Powder inhaler formulations
MY129263A (en) Vaccine composition
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2000007979A3 (en) Compounds and compositions for delivering active agents
WO2003002136A3 (en) Stable formulation of modified glp-1
WO2001005355A3 (en) Formulations for il-11
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
GB0100758D0 (en) Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
WO2002101412A3 (en) Spray freeze-dried compositions
MY119181A (en) Aryl pyrimidine derivatives
EP1024145A3 (en) Novel azalides and methods of making same
EP1327449A4 (en) MEDICINE FOR THE TREATMENT OF ISCHEMIC ILLNESSES
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
WO2004017918A9 (en) Method of preparing dry powder inhalation compositions
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
CA2461517A1 (en) Nicotine formulations comprising cocoa and use thereof
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
WO2005048985A3 (en) Alpha 1-antitrypsin compositions and treatment methods using such compositions
WO2002070464A3 (en) Hydrazones and their therapeutic use

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: NEKTAR THERAPEUTICS

Free format text: FORMER OWNER(S): NEKTAR THERAPEUTICS, ELI LILLY AND COMPANY